James P. Allison of US and Tasuku Honjo of Japan shared the 2018 Nobel Prize in Physiology or Medicine for “therapy for the discovery of negative immunomodulation for cancer treatment”. As manyRead More…
New T-Cell Therapy Is Expected to Eliminate the HIV in the Human Body
Anti-retroviral therapy (ART) revolutionized the treatment of human immunodeficiency virus (HIV), the pathogen of acquired immunodeficiency syndrome (AIDS), but fatal AIDS still cannot be cured mainly due to the presence of aRead More…
Two CAR-T Products Were Approved by the European Union for the First Time
Cancer immunotherapy that is given to attention long time has recently made tremendous progress. Novartis’s Kymriah and Gilead’s Yescarta, two star CAR-T products, were approved by the European Union (EU) and becameRead More…
Review: The Expansion of Targetable Biomarkers for CAR T Cell Therapy
A recently published report summarizes the biomarker targets in both hematological and solid malignancies for CAR T cell therapy and discusses potential new biomarker target. A biomarker is an integral part ofRead More…
FDA Approved CAR-macrophage Therapy of Ovarian Cancer into Clinical Trials
Recently, MaxCyte announced that the company’s chimeric antigen receptor (CAR) cell therapy for the treatment of solid tumors based on non-viral messenger RNA (mRNA) technology has been approved by the Food andRead More…
Cytokine Release Syndrome Caused by CAR-T Therapy
Chimeric antigen receptor T cell (CAR-T) therapy is a novel cellular immunotherapy method that introduces chimeric antigen receptors and costimulatory molecules targeting specific targets into T cells by gene editing technology. TumorRead More…
CAR-NK: Safer, Cheaper and Better Anti-cancer Drug
At the end of June this year, the CAR-NK cell, a new immune cell, was reported as the third CAR cell to fight against cancer after CAR-T cells and CAR-macrophage cells. TheRead More…
PD1 VS CTLA-4: Which Works Better in the Combination Therapy with Oncolytic Virus?
Cancers don’t come from anything but result from unexpected mutations in human cells with the uncontrolled proliferation of cells as the most important feature. The cells in the body undergo mutations atRead More…
Hot Issues Tracking—Present and Future of Oncolytic Virus
On May 2, Johnson & Johnson, a pharmaceutical giant, announced that it has invested $1 billion in the acquisition of BeneVir Biopharm, a biotech-company dedicated to oncolytic virus immunotherapy research. This newsRead More…
What Is Immunotherapy？
A 72-year-old Connecticut citizen Bob Carlson was diagnosed with lung cancer four years ago. The doctor estimates that he will not live longer than two years. He tried a variety of programsRead More…